In a report published by Goldman Sachs, analyst Andrew Rosivach resumed coverage on Ventas VTR with a Buy rating and 12-month $88 price target.
Goldman Sachs reported that, “We are resuming coverage of Ventas (VTR) with a Buy rating, relative to our Attractive healthcare coverage view, and a 12-month price target of $88 (30% upside including dividends). Our model forecasts a sturdy 74% AFFO growth rate (1% above our coverage universe average). We believe VTR's 26% exposure to RIDEA senior
housing, where supply-demand fundamentals are very favorable, should give the company the best internal
growth outlook in the healthcare sector.”
Shares of Ventas closed at $69.89 on Wednesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in